Pharmacology Quiz: Neuromuscular Blockers
20 questions · exam conditions
0:00
Neuromuscular BlockersQuestion 1 of 20

A patient receives a prolonged infusion of succinylcholine, and the neuromuscular block transitions from Phase I to Phase II. Which of the following findings would be most indicative of this transition?

The paralysis is intensified by the administration of an acetylcholinesterase inhibitor.
Train-of-four stimulation shows four equal-sized, though diminished, twitches.
The block is now characterized by fade on train-of-four stimulation and is partially reversed by neostigmine.
Spontaneous recovery from the block occurs more rapidly than it did during the initial phase.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Neuromuscular Blockers

Practice Neuromuscular Blockers in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Neuromuscular Blockers, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient receives a prolonged infusion of succinylcholine, and the neuromuscular block transitions from Phase I to Phase II. Which of the following findings would be most indicative of this transition?

  1. The paralysis is intensified by the administration of an acetylcholinesterase inhibitor.
  2. Train-of-four stimulation shows four equal-sized, though diminished, twitches.
  3. The block is now characterized by fade on train-of-four stimulation and is partially reversed by neostigmine. (correct answer)
  4. Spontaneous recovery from the block occurs more rapidly than it did during the initial phase.
Explanation: Phase II block, which occurs after prolonged exposure to succinylcholine, clinically resembles a nondepolarizing block. Its key feature is the appearance of 'fade' on train-of-four (TOF) or tetanic stimulation. Paradoxically, unlike a Phase I block which is potentiated by acetylcholinesterase inhibitors, a Phase II block can be partially antagonized by them.

Question 2

During surgery, neuromuscular function is monitored with a peripheral nerve stimulator. The train-of-four (TOF) response shows four twitches, with the height of the fourth twitch being only 30% of the first (TOF ratio = 0.3). Administration of edrophonium leads to an increase in the TOF ratio to 0.8. This clinical picture is most consistent with which type of neuromuscular blocker?

  1. A depolarizing blocker in Phase I.
  2. A nondepolarizing blocker. (correct answer)
  3. A depolarizing blocker in Phase II.
  4. A centrally acting muscle relaxant.
Explanation: This question requires two steps. First, the presence of 'fade' (TOF ratio < 0.9) indicates either a nondepolarizing block or a Phase II depolarizing block. Second, the block is reversed by edrophonium, an acetylcholinesterase inhibitor. This combination of fade and reversibility by an anticholinesterase is the classic profile of a nondepolarizing (competitive) neuromuscular blocker.

Question 3

In a patient with myasthenia gravis, there is a significant reduction in the number of functional nicotinic acetylcholine receptors at the neuromuscular junction. How does this condition affect the patient's sensitivity to succinylcholine and vecuronium?

  1. Increased sensitivity to both succinylcholine and vecuronium.
  2. Decreased sensitivity (resistance) to succinylcholine and increased sensitivity to vecuronium. (correct answer)
  3. Increased sensitivity to succinylcholine and decreased sensitivity (resistance) to vecuronium.
  4. Decreased sensitivity (resistance) to both succinylcholine and vecuronium.
Explanation: Patients with myasthenia gravis have fewer ACh receptors. Succinylcholine (an agonist) requires these receptors to cause depolarization; with fewer targets, a larger dose is needed, indicating resistance. In contrast, vecuronium (a competitive antagonist) needs to block a smaller number of receptors to achieve paralysis. Therefore, a standard dose has an exaggerated effect, indicating increased sensitivity.

Question 4

A patient receives a drug that causes brief, visible muscle fasciculations followed by paralysis. A subsequent dose of neostigmine is administered while the paralysis is still profound. What is the most likely outcome?

  1. Rapid reversal of the paralysis.
  2. No change in the depth of the blockade.
  3. Intensification and prolongation of the paralysis. (correct answer)
  4. Development of spastic paralysis.
Explanation: The initial fasciculations indicate the use of a depolarizing blocker like succinylcholine, which results in a Phase I block. Neostigmine, an acetylcholinesterase inhibitor, increases the amount of acetylcholine at the synapse. During a Phase I block, the motor end plate is already depolarized by succinylcholine. The additional acetylcholine will further contribute to this depolarization, thereby intensifying and prolonging the block rather than reversing it.

Question 5

A patient in the intensive care unit is receiving intravenous gentamicin for a gram-negative infection and is also receiving intermittent boluses of vecuronium to facilitate mechanical ventilation. The clinician should be aware of a potential drug interaction that would most likely result in:

  1. decreased duration of action of vecuronium.
  2. antagonism of gentamicin's antimicrobial effects.
  3. rapid development of tolerance to vecuronium.
  4. potentiation and prolongation of the neuromuscular blockade. (correct answer)
Explanation: When you encounter questions about drug interactions in pharmacology, focus on the mechanisms of action and how drugs might enhance or interfere with each other's effects at the cellular level. Gentamicin belongs to the aminoglycoside class of antibiotics, which has a well-documented ability to block neuromuscular transmission. Aminoglycosides interfere with calcium influx at the presynaptic nerve terminal, reducing acetylcholine release, and they also have some postsynaptic blocking effects at the neuromuscular junction. Vecuronium is a non-depolarizing neuromuscular blocking agent that competitively blocks acetylcholine receptors at the motor endplate. When used together, gentamicin enhances vecuronium's neuromuscular blocking effects through this additive mechanism, leading to answer D - potentiation and prolongation of the neuromuscular blockade. Answer A suggests decreased duration, which contradicts the actual pharmacologic interaction - the blockade is enhanced, not shortened. Answer B implies that vecuronium would interfere with gentamicin's antibacterial activity, but neuromuscular blockers don't affect antibiotic mechanisms against bacteria. Answer C mentions tolerance development, but this interaction is about immediate pharmacodynamic enhancement, not the gradual receptor adaptation that characterizes tolerance. Remember this key pattern: aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) can significantly enhance neuromuscular blockade from any neuromuscular blocking agent. This is a high-yield interaction that's clinically significant in ICU settings where both drug classes are commonly used together.

Question 6

A patient receiving a stable infusion of cisatracurium for neuromuscular blockade develops acute respiratory acidosis. How is this change in acid-base status expected to influence the effect of cisatracurium?

  1. It will potentiate the neuromuscular blockade. (correct answer)
  2. It will antagonize the neuromuscular blockade.
  3. It will accelerate the Hofmann elimination of cisatracurium.
  4. It will have no effect on the neuromuscular blockade.
Explanation: Respiratory acidosis (and metabolic acidosis) is known to potentiate the effects of nondepolarizing neuromuscular blockers. The exact mechanism is complex but may involve decreased plasma protein binding, altered ionization of the drug, and direct effects on the neuromuscular junction. This potentiation means that a lower infusion rate would be required to maintain the same level of blockade.

Question 7

A 40-year-old patient with a severe crush injury to both lower extremities requires emergency surgery. The selection of a neuromuscular blocker for rapid sequence intubation must be made carefully. Which agent is generally contraindicated in this patient due to the risk of a life-threatening electrolyte abnormality?

  1. Rocuronium, due to risk of severe hypokalemia.
  2. Succinylcholine, due to risk of severe hyperkalemia. (correct answer)
  3. Atracurium, due to risk of histamine-mediated hypernatremia.
  4. Vecuronium, due to risk of severe hypocalcemia.
Explanation: In patients with crush injuries, extensive burns, or upper motor neuron lesions, there is an upregulation of extrajunctional nicotinic acetylcholine receptors. Administration of succinylcholine, a depolarizing agent, causes these channels to open, leading to a massive efflux of potassium from cells into the bloodstream. This can result in life-threatening hyperkalemia and cardiac arrest.

Question 8

A patient is paralyzed with rocuronium. The anesthesiologist decides to reverse the blockade with sugammadex instead of neostigmine. What is the fundamental difference in the mechanism of reversal by sugammadex compared to neostigmine?

  1. Sugammadex increases acetylcholine levels at the synapse, while neostigmine directly inactivates rocuronium.
  2. Sugammadex is an acetylcholinesterase inhibitor, while neostigmine is a selective receptor antagonist.
  3. Sugammadex directly encapsulates rocuronium molecules in the plasma, while neostigmine indirectly increases synaptic acetylcholine. (correct answer)
  4. Sugammadex accelerates the hepatic metabolism of rocuronium, while neostigmine prevents its renal excretion.
Explanation: Sugammadex has a unique mechanism of action. It is a modified gamma-cyclodextrin that directly encapsulates aminosteroid neuromuscular blockers like rocuronium in the plasma. This binding is very strong, creating a concentration gradient that pulls rocuronium away from the neuromuscular junction, leading to rapid reversal. This is fundamentally different from neostigmine, which acts indirectly by inhibiting acetylcholinesterase to increase acetylcholine levels for receptor competition.

Question 9

A patient under general anesthesia has received rocuronium for muscle relaxation. At the conclusion of the surgery, the anesthesiologist administers neostigmine. What is the primary mechanism by which neostigmine reverses the effects of rocuronium?

  1. By increasing the metabolic breakdown of rocuronium in the liver.
  2. By directly binding to rocuronium and inactivating it in the plasma.
  3. By inhibiting acetylcholinesterase, leading to increased acetylcholine concentrations at the synapse. (correct answer)
  4. By blocking presynaptic nicotinic receptors to enhance acetylcholine release.
Explanation: Neostigmine is an acetylcholinesterase inhibitor. By inhibiting this enzyme, it prevents the breakdown of acetylcholine (ACh) in the neuromuscular junction. The resulting increase in ACh concentration allows ACh to outcompete the nondepolarizing blocker (rocuronium) for binding sites on the postsynaptic nicotinic receptors, thereby restoring neuromuscular transmission.

Question 10

Which of the following structural and metabolic characteristics is unique to succinylcholine compared to aminosteroid (e.g., rocuronium) or benzylisoquinolinium (e.g., atracurium) nondepolarizing blockers?

  1. It is a large, bulky molecule that sterically hinders the acetylcholine receptor.
  2. It is composed of two acetylcholine molecules linked end-to-end and is hydrolyzed by plasma cholinesterase. (correct answer)
  3. It undergoes spontaneous, non-enzymatic degradation at physiological pH and temperature (Hofmann elimination).
  4. It is primarily metabolized by hepatic cytochrome P450 enzymes and eliminated via the biliary system.
Explanation: Succinylcholine's structure is essentially two molecules of acetylcholine joined together. This structure allows it to act as an agonist. Its rapid breakdown by plasma butyrylcholinesterase (pseudocholinesterase) is its key metabolic feature, responsible for its short duration of action. The other options describe features of various nondepolarizing agents.

Question 11

A 40-year-old patient with a severe crush injury to both lower extremities requires emergency surgery. The selection of a neuromuscular blocker for rapid sequence intubation must be made carefully. Which agent is generally contraindicated in this patient due to the risk of a life-threatening electrolyte abnormality?

  1. Rocuronium, due to risk of severe hypokalemia.
  2. Succinylcholine, due to risk of severe hyperkalemia. (correct answer)
  3. Atracurium, due to risk of histamine-mediated hypernatremia.
  4. Vecuronium, due to risk of severe hypocalcemia.
Explanation: In patients with crush injuries, extensive burns, or upper motor neuron lesions, there is an upregulation of extrajunctional nicotinic acetylcholine receptors. Administration of succinylcholine, a depolarizing agent, causes these channels to open, leading to a massive efflux of potassium from cells into the bloodstream. This can result in life-threatening hyperkalemia and cardiac arrest.

Question 12

A patient receives a prolonged infusion of succinylcholine, and the neuromuscular block transitions from Phase I to Phase II. Which of the following findings would be most indicative of this transition?

  1. The paralysis is intensified by the administration of an acetylcholinesterase inhibitor.
  2. Train-of-four stimulation shows four equal-sized, though diminished, twitches.
  3. The block is now characterized by fade on train-of-four stimulation and is partially reversed by neostigmine. (correct answer)
  4. Spontaneous recovery from the block occurs more rapidly than it did during the initial phase.
Explanation: Phase II block, which occurs after prolonged exposure to succinylcholine, clinically resembles a nondepolarizing block. Its key feature is the appearance of 'fade' on train-of-four (TOF) or tetanic stimulation. Paradoxically, unlike a Phase I block which is potentiated by acetylcholinesterase inhibitors, a Phase II block can be partially antagonized by them.

Question 13

In a patient with myasthenia gravis, there is a significant reduction in the number of functional nicotinic acetylcholine receptors at the neuromuscular junction. How does this condition affect the patient's sensitivity to succinylcholine and vecuronium?

  1. Increased sensitivity to both succinylcholine and vecuronium.
  2. Decreased sensitivity (resistance) to succinylcholine and increased sensitivity to vecuronium. (correct answer)
  3. Increased sensitivity to succinylcholine and decreased sensitivity (resistance) to vecuronium.
  4. Decreased sensitivity (resistance) to both succinylcholine and vecuronium.
Explanation: Patients with myasthenia gravis have fewer ACh receptors. Succinylcholine (an agonist) requires these receptors to cause depolarization; with fewer targets, a larger dose is needed, indicating resistance. In contrast, vecuronium (a competitive antagonist) needs to block a smaller number of receptors to achieve paralysis. Therefore, a standard dose has an exaggerated effect, indicating increased sensitivity.

Question 14

A patient receiving a stable infusion of cisatracurium for neuromuscular blockade develops acute respiratory acidosis. How is this change in acid-base status expected to influence the effect of cisatracurium?

  1. It will potentiate the neuromuscular blockade. (correct answer)
  2. It will antagonize the neuromuscular blockade.
  3. It will accelerate the Hofmann elimination of cisatracurium.
  4. It will have no effect on the neuromuscular blockade.
Explanation: Respiratory acidosis (and metabolic acidosis) is known to potentiate the effects of nondepolarizing neuromuscular blockers. The exact mechanism is complex but may involve decreased plasma protein binding, altered ionization of the drug, and direct effects on the neuromuscular junction. This potentiation means that a lower infusion rate would be required to maintain the same level of blockade.

Question 15

A patient is given an unknown neuromuscular blocking agent. Monitoring with a peripheral nerve stimulator reveals that the twitch height in response to single stimuli is reduced by 80%, but the train-of-four ratio remains 1.0.

Based on the monitoring data from the passage, which statement accurately describes the patient's condition?

  1. The patient has a nondepolarizing block that can be readily reversed with neostigmine.
  2. The patient has received a centrally acting muscle relaxant, not a neuromuscular blocker.
  3. The patient has a depolarizing block that has transitioned to Phase II.
  4. The patient has a depolarizing block in Phase I. (correct answer)
Explanation: When evaluating neuromuscular blockade, you need to understand how different types of blocks affect nerve stimulation patterns. The key monitoring parameters are twitch height reduction and the train-of-four (TOF) ratio, which reveal distinct patterns for depolarizing versus nondepolarizing blocks. The monitoring data shows 80% twitch height reduction with a TOF ratio of 1.0. This pattern is pathognomonic for Phase I depolarizing block. In this phase, succinylcholine causes sustained depolarization of the motor endplate, making it unresponsive to further stimulation. Importantly, all four twitches in the train-of-four are equally diminished, maintaining a ratio of 1.0 even as overall strength decreases. Option A is incorrect because nondepolarizing blocks characteristically produce fade, where the TOF ratio drops below 1.0 as later twitches become progressively weaker. Option B misses the mark entirely—the significant twitch height reduction clearly indicates neuromuscular junction blockade, not central nervous system effects. Option C describes Phase II block, which occurs with prolonged succinylcholine exposure and actually resembles nondepolarizing block with fade (TOF ratio < 1.0). Remember this pattern: Phase I depolarizing block = reduced twitch height + TOF ratio of 1.0. This combination is unique to early succinylcholine effects. When you see preserved TOF ratio despite significant weakness, think depolarizing block in Phase I. Conversely, any fade (TOF < 1.0) suggests either nondepolarizing block or Phase II depolarizing block.

Question 16

A patient is paralyzed with rocuronium. The anesthesiologist decides to reverse the blockade with sugammadex instead of neostigmine. What is the fundamental difference in the mechanism of reversal by sugammadex compared to neostigmine?

  1. Sugammadex increases acetylcholine levels at the synapse, while neostigmine directly inactivates rocuronium.
  2. Sugammadex is an acetylcholinesterase inhibitor, while neostigmine is a selective receptor antagonist.
  3. Sugammadex directly encapsulates rocuronium molecules in the plasma, while neostigmine indirectly increases synaptic acetylcholine. (correct answer)
  4. Sugammadex accelerates the hepatic metabolism of rocuronium, while neostigmine prevents its renal excretion.
Explanation: Sugammadex has a unique mechanism of action. It is a modified gamma-cyclodextrin that directly encapsulates aminosteroid neuromuscular blockers like rocuronium in the plasma. This binding is very strong, creating a concentration gradient that pulls rocuronium away from the neuromuscular junction, leading to rapid reversal. This is fundamentally different from neostigmine, which acts indirectly by inhibiting acetylcholinesterase to increase acetylcholine levels for receptor competition.

Question 17

Which of the following structural and metabolic characteristics is unique to succinylcholine compared to aminosteroid (e.g., rocuronium) or benzylisoquinolinium (e.g., atracurium) nondepolarizing blockers?

  1. It is a large, bulky molecule that sterically hinders the acetylcholine receptor.
  2. It is composed of two acetylcholine molecules linked end-to-end and is hydrolyzed by plasma cholinesterase. (correct answer)
  3. It undergoes spontaneous, non-enzymatic degradation at physiological pH and temperature (Hofmann elimination).
  4. It is primarily metabolized by hepatic cytochrome P450 enzymes and eliminated via the biliary system.
Explanation: Succinylcholine's structure is essentially two molecules of acetylcholine joined together. This structure allows it to act as an agonist. Its rapid breakdown by plasma butyrylcholinesterase (pseudocholinesterase) is its key metabolic feature, responsible for its short duration of action. The other options describe features of various nondepolarizing agents.

Question 18

During surgery, neuromuscular function is monitored with a peripheral nerve stimulator. The train-of-four (TOF) response shows four twitches, with the height of the fourth twitch being only 30% of the first (TOF ratio = 0.3). Administration of edrophonium leads to an increase in the TOF ratio to 0.8. This clinical picture is most consistent with which type of neuromuscular blocker?

  1. A depolarizing blocker in Phase I.
  2. A nondepolarizing blocker. (correct answer)
  3. A depolarizing blocker in Phase II.
  4. A centrally acting muscle relaxant.
Explanation: This question requires two steps. First, the presence of 'fade' (TOF ratio < 0.9) indicates either a nondepolarizing block or a Phase II depolarizing block. Second, the block is reversed by edrophonium, an acetylcholinesterase inhibitor. This combination of fade and reversibility by an anticholinesterase is the classic profile of a nondepolarizing (competitive) neuromuscular blocker.

Question 19

The recovery of muscle function after administration of a nondepolarizing neuromuscular blocker follows a predictable pattern. Which muscle group is typically the first to regain function?

  1. Muscles of the hand and feet.
  2. Muscles of the face and eyes.
  3. Muscles of the trunk and abdomen.
  4. Muscles of respiration (diaphragm). (correct answer)
Explanation: Paralysis from nondepolarizing blockers typically begins in small, rapidly moving muscles (eyes, fingers) and progresses to larger trunk muscles, and finally the diaphragm. The diaphragm is the most resistant to blockade and therefore the last muscle group to be paralyzed and the first to recover. Recovery occurs in reverse order of onset.

Question 20

When selecting a neuromuscular blocker for a patient with a known family history of malignant hyperthermia (MH), succinylcholine is absolutely contraindicated. This is because succinylcholine, unlike nondepolarizing blockers, can:

  1. trigger an uncontrolled release of calcium from the sarcoplasmic reticulum in susceptible individuals. (correct answer)
  2. cause a precipitous drop in plasma cholinesterase activity, leading to prolonged paralysis.
  3. induce massive histamine release from mast cells, resulting in refractory hypotension.
  4. directly inhibit mitochondrial respiration, leading to severe lactic acidosis.
Explanation: Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle. In susceptible individuals, triggering agents like succinylcholine (and volatile anesthetics) cause a defect in the ryanodine receptor (RyR1), leading to a massive and uncontrolled release of Ca²⁺ from the sarcoplasmic reticulum. This results in the hypermetabolic state characteristic of an MH crisis (muscle rigidity, hyperthermia, acidosis, etc.).